Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Oseltamivir acid: Potent Influenza Neuraminidase Inhibito...

    2025-12-28

    Oseltamivir acid: Molecular Benchmark for Influenza Neuraminidase Inhibition

    Executive Summary: Oseltamivir acid is the active metabolite of the prodrug oseltamivir, directly inhibiting influenza viral neuraminidase and blocking the release of progeny virions (APExBIO). Its solubility and chemical stability parameters are well-characterized, supporting robust laboratory workflows. In vitro, it significantly reduces sialidase activity and cell viability in breast cancer cell lines, especially in combination with chemotherapeutic agents. In vivo, oseltamivir acid suppresses tumor growth and metastasis in xenograft mouse models at defined dose ranges. Resistance can arise via H275Y neuraminidase mutations, impacting antiviral efficacy (Yang et al., 2025).

    Biological Rationale

    Influenza virus replication relies on neuraminidase, an enzyme that cleaves terminal sialic acid residues from host cell glycoproteins and newly formed virions. This process is essential for the release of infectious viral particles and the spread of infection to new host cells (Oseltamivir Acid: Influenza Neuraminidase Inhibitor for R...). Oseltamivir acid, a neuraminidase inhibitor for influenza treatment, is designed to block this critical step, limiting virus transmission and disease severity. Neuraminidase inhibitors like oseltamivir acid have also been explored for their effects on cell surface sialylation in cancer biology, where sialidase activity may facilitate metastasis (Oseltamivir Acid: Influenza Neuraminidase Inhibitor Innov...).

    Mechanism of Action of Oseltamivir acid

    Oseltamivir acid is generated in vivo from the orally administered prodrug oseltamivir by intestinal and hepatic esterases (Yang et al., 2025). The active acid binds to the active site of influenza neuraminidase, competitively inhibiting its sialidase function. This prevents cleavage of α-Neu5Ac residues from viral and cellular glycoproteins, thereby blocking virion release from infected cells. The result is a marked reduction in viral propagation and attenuation of influenza symptoms. Oseltamivir acid does not inhibit other viral enzymes or directly affect host cell DNA/RNA synthesis under standard laboratory conditions.

    Evidence & Benchmarks

    • Oseltamivir acid demonstrates ≥46.1 mg/mL solubility in water at gentle warming, enabling preparation of high-concentration stock solutions for in vitro assays (APExBIO).
    • In MDA-MB-231 and MCF-7 breast cancer cell lines, oseltamivir acid reduces neuraminidase (sialidase) activity and cell viability in a dose-dependent manner (10–100 μM, 48 h) (APExBIO).
    • Combination treatment with standard chemotherapeutics (Cisplatin, 5-FU, Paclitaxel, Gemcitabine, Tamoxifen) and oseltamivir acid yields synergistic cytotoxicity in vitro (APExBIO).
    • In vivo, intraperitoneal administration of oseltamivir acid at 30–50 mg/kg in RAGxCγ double mutant mice with MDA-MB-231 xenografts results in significant inhibition of tumor vascularization, growth, and metastasis (p < 0.05), with high-dose regimens (50 mg/kg) achieving complete tumor progression ablation and improved long-term survival (APExBIO).
    • Resistance to oseltamivir acid is primarily associated with H275Y mutation in the neuraminidase gene, compromising inhibitor binding (Yang et al., 2025).
    • Humanized mouse models are superior to standard murine models for predicting ester prodrug activation (e.g., oseltamivir to oseltamivir acid) due to species-specific carboxylesterase distributions (Yang et al., 2025).

    This article extends "Oseltamivir Acid: Unraveling Mechanisms & Next-Gen Influenza Antivirals" by providing a more granular, evidence-backed synthesis of workflow parameters and resistance mechanisms, while the referenced article focuses on translational modeling strategies.

    Applications, Limits & Misconceptions

    Oseltamivir acid is primarily used as a research tool for studying influenza virus replication inhibition and antiviral drug development. Its secondary application in cancer models is based on its ability to block viral and cellular sialidase activity, which may impact tumor metastasis (Oseltamivir Acid at the Translational Frontier: Mechanist...). However, these oncology applications remain investigational and are not clinically validated.

    Common Pitfalls or Misconceptions

    • Oseltamivir acid is not effective against non-influenza viruses, as their replication does not depend on neuraminidase.
    • Resistance mutations (H275Y) in neuraminidase can render oseltamivir acid ineffective, necessitating genotypic surveillance in experimental designs (Yang et al., 2025).
    • Long-term storage of oseltamivir acid solutions (especially at room temperature) leads to compound degradation; fresh preparations are recommended for reliability (APExBIO).
    • Human pharmacokinetics and metabolism may not be accurately predicted from standard mouse models due to species-specific carboxylesterase expression; humanized mice provide superior translational accuracy.
    • Oseltamivir acid is not a substitute for clinically approved influenza therapies when used outside controlled research settings.

    Workflow Integration & Parameters

    • Solubility: ≥46.1 mg/mL in water (gentle warming), ≥14.2 mg/mL in DMSO, ≥97 mg/mL in ethanol (gentle warming) (APExBIO).
    • Storage conditions: -20°C (dry powder); avoid long-term solution storage for stability.
    • In vitro use: Typical concentrations range from 1–100 μM; adjust based on cell type and endpoint.
    • In vivo dosing: Intraperitoneal injection at 30–50 mg/kg/day in mouse models has been validated for tumor inhibition studies.
    • Resistance monitoring: Genotype viral neuraminidase to detect H275Y or other resistance mutations before efficacy studies.

    For detailed protocols and troubleshooting, see the A3689 kit documentation and APExBIO’s product page.

    Conclusion & Outlook

    Oseltamivir acid is a canonical influenza neuraminidase inhibitor with well-validated anti-influenza activity and emerging roles in cancer metastasis inhibition. Its robust solubility, stability, and mechanistic specificity make it a preferred research standard for viral sialidase activity blockade and antiviral drug development. Future studies will benefit from species-specific metabolic models and ongoing resistance surveillance. For additional context and advanced modeling protocols, readers are encouraged to consult "Oseltamivir Acid: Precision Tools for Influenza and Cancer", which complements this article with a focus on translational workflows and modeling strategies.